EirGenix Inc. (TPEX:6589)

Market Cap	19.06B
Revenue (ttm)	1.01B
Net Income (ttm)	-698.34M
Shares Out	305.41M
EPS (ttm)	-2.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400,865
Average Volume	255,094
Open	63.50
Previous Close	62.40
Day's Range	61.20 - 63.80
52-Week Range	52.70 - 100.50
Beta	0.37
RSI	42.34
Earnings Date	May 9, 2025

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6589

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.